Hunan Fangsheng Pharmaceutical (603998.SH) announced its semi-annual report for 2024, with the company achieving a revenue of 0.91 billion yuan during the reporting period.
According to the disclosure of the semi-annual report for 2024, Hunan Fangsheng Pharmaceutical (603998.SH) achieved a revenue of 0.91 billion yuan, a year-on-year increase of 6.44%; net income attributable to shareholders was 0.137 billion yuan, a year-on-year increase of 28.23%; non-GAAP net income was 0.111 billion yuan, a year-on-year increase of 26.54%; and basic earnings per share were 0.32 yuan.